tetano
Editor, Senior Moderator
Cureus
. 2022 May 19;14(5):e25150.
doi: 10.7759/cureus.25150. eCollection 2022 May.
A Case of Right Ventricular Thrombus in a Patient With Recent COVID-19 Infection
Andreas Mitsis[SUP] 1 [/SUP], Aggelos Alexi[SUP] 1 [/SUP], Thrasos Constantinides[SUP] 2 [/SUP], Grigorios Chatzantonis[SUP] 3 [/SUP], Panayiotis Avraamides[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The respiratory system is the main target of the virus; however, apart from lung disease, a relatively large proportion of patients develop thrombosis as well. We present the case of a 19-year-old male who was admitted after contracting community-acquired right-sided pneumonia. The patient had a history of COVID-19 infection four weeks before admission. The echocardiographic assessment revealed a 16 x 6-mm right ventricular (RV) thrombus. He underwent a cardiovascular magnetic resonance (CMR) study, which confirmed the findings. After ruling out the most common causes of hypercoagulability, COVID-19 was judged to be the cause of the thrombus. The patient was treated with warfarin. Follow-up imaging with echocardiography and CMR six months later revealed complete resolution of the thrombus. Hypercoagulability is a major complication of COVID-19 and in situ thrombosis can occur both in the arterial and venous circulation. The recognition of intracardiac thrombi even in low-risk patients with a history of COVID-19 infection and the immediate initiation of antithrombotic treatment to minimize the risk of embolization is of paramount importance. Advanced imaging techniques are often required to establish the diagnosis of this condition.
Keywords: cardiac magnetic resonance (cmr); coronavirus disease 2019 (covid-19); intracardiac thrombosis; right ventricular thrombus; ventricular thrombosis.
. 2022 May 19;14(5):e25150.
doi: 10.7759/cureus.25150. eCollection 2022 May.
A Case of Right Ventricular Thrombus in a Patient With Recent COVID-19 Infection
Andreas Mitsis[SUP] 1 [/SUP], Aggelos Alexi[SUP] 1 [/SUP], Thrasos Constantinides[SUP] 2 [/SUP], Grigorios Chatzantonis[SUP] 3 [/SUP], Panayiotis Avraamides[SUP] 1 [/SUP]
Affiliations
- PMID: 35747016
- PMCID: PMC9206708
- DOI: 10.7759/cureus.25150
Abstract
Coronavirus disease 2019 (COVID-19) is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The respiratory system is the main target of the virus; however, apart from lung disease, a relatively large proportion of patients develop thrombosis as well. We present the case of a 19-year-old male who was admitted after contracting community-acquired right-sided pneumonia. The patient had a history of COVID-19 infection four weeks before admission. The echocardiographic assessment revealed a 16 x 6-mm right ventricular (RV) thrombus. He underwent a cardiovascular magnetic resonance (CMR) study, which confirmed the findings. After ruling out the most common causes of hypercoagulability, COVID-19 was judged to be the cause of the thrombus. The patient was treated with warfarin. Follow-up imaging with echocardiography and CMR six months later revealed complete resolution of the thrombus. Hypercoagulability is a major complication of COVID-19 and in situ thrombosis can occur both in the arterial and venous circulation. The recognition of intracardiac thrombi even in low-risk patients with a history of COVID-19 infection and the immediate initiation of antithrombotic treatment to minimize the risk of embolization is of paramount importance. Advanced imaging techniques are often required to establish the diagnosis of this condition.
Keywords: cardiac magnetic resonance (cmr); coronavirus disease 2019 (covid-19); intracardiac thrombosis; right ventricular thrombus; ventricular thrombosis.